Alnylam gets CHMP backing for second gene-silencing drug GivlaariAlnylam could be weeks away from getting its second RNA interference drug approved in Europe, after a CHMP Share XAlnylam gets CHMP backing for second gene-silencing drug Givlaarihttps://pharmaphorum.com/news/alnylam-gets-chmp-backing-for-second-gene-silencing-drug-givlaari/
TMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?Cardiologists only had to wait a few days after The Medicines Company teased top-line results with its cholesterol-lowering Share XTMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?https://pharmaphorum.com/news/tmcs-inclisiran-impresses-at-esc-but-will-it-surpass-pcsk9-rivals/
Alnylam gears up for first RNAi therapeutic filing in 2017US biotech Alnylam says it could file its first product in 2017, a rare disease drug using what Share XAlnylam gears up for first RNAi therapeutic filing in 2017https://pharmaphorum.com/news/alnylam-gears-up-for-first-rnai-therapeutic-filing-in-2017/
